For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

13th Dec 10

Bronchitol Recommended for Approval by Australian Advisory Committee

Pharmaxis today announced that at its recent meeting, the Australian Advisory Committee on Prescription Medicines (ACPM) has recommended approval of Bronchitol (inhaled dry powder mannitol) for marketing in Australia for the treatment of cystic fibrosis.


Read full media release - pdf
7th Dec 10

Phase II Trial of ASM8 in Asthma Commences

Pharmaxis today announced it had enrolled the first subjects into a Phase II clinical trial evaluating the new asthma drug, ASM8, in patients with allergic asthma.


Read full media release - pdf
22nd Oct 10

Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results

Pharmaxis today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.


Read full media release - pdf